{"id":15850,"date":"2026-10-15T21:26:55","date_gmt":"2026-10-15T21:26:55","guid":{"rendered":"https:\/\/alsuprun.com\/blog\/?p=15850"},"modified":"2026-10-15T21:27:06","modified_gmt":"2026-10-15T21:27:06","slug":"vibroacoustic-stimulation-pregnancy","status":"publish","type":"post","link":"https:\/\/alsuprun.com\/blog\/vibroacoustic\/vibroacoustic-stimulation-pregnancy\/","title":{"rendered":"Vibroacoustic Stimulation Pregnancy"},"content":{"rendered":"

Vibroacoustic stimulation<\/a> pregnancy is an easy non-stress test to assess the fetus’ well being. This is an important tool in high risk pregnancies to help doctors know whether the baby is safe and healthy.<\/p>\n

Current methods of assessing fetal wellbeing, such as antepartum fetal heart rate monitoring and fetal movement counts, are time consuming, expensive and sometimes inaccurate.<\/p>\n

Background<\/h2>\n

Vibroacoustic Stimulation<\/a> (VAS) is a non-invasive technique used in pregnancy to determine the well being of a pregnant woman\u2019s unborn baby. This test uses a vibrating platform to stimulate the fetus and provoke a reaction from it such as a change in heart rate or movement. This allows healthcare providers to evaluate the fetus\u2019s condition and behavior more effectively than with other monitoring methods. This method has been shown to decrease the false positive rates of non-reactive cardiotocograph (CTG) tests, which can result in unnecessary interventions such as induced labour or Caesarean section.<\/p>\n

The use of VAS has been incorporated into many antepartum care routines around the world to reduce the time and cost associated with invasive testing such as CTG. However, there is a need for additional studies and trials to establish its effectiveness in predicting fetal risk and improving perinatal outcomes.<\/p>\n

A systematic review of 12 randomised controlled trials involving 6822 women was performed to assess the efficacy of fetal vibroacoustic stimulation<\/a> in conjunction with tests of fetal wellbeing. This study excluded all non-randomised, quasi-randomised, case\u2013control and observational studies, as well as those evaluating different intensities of the stimuli or other factors such as maternal satisfaction, maternal anxiety and antenatal complications (Bolnick 2006; Gonzalez 1998; Newnham 1990; Papadopoulos 2007; Pinette 2005).<\/p>\n

Results showed that compared with a standard fetal heart rate trace, a VAS-evoked response was more reliable in all trials except the trial by Tongsong. The other nine trials found that a VAS-evoked response was associated with less frequent non-reactive fetal heart rate tracings and a higher percentage of fetal contractions (one trial; RR 0.62, 95% CI 0.45-0.88). However, data on fetal distress and perinatal deaths were too few to draw any conclusions.<\/p>\n

The ability of a fetal vibration stimulus to evoke a reaction is dependent on its intensity, frequency and duration and the position of the fetus. This is why it is essential that future randomised trials determine the optimum intensity, frequency and duration of the fetal vibration stimulus and evaluate its safety and perinatal outcome when used with tests of fetal wellbeing.<\/p>\n

Methods<\/h2>\n

Fetal VAS involves placing a vibrating device on the maternal abdomen, over the region of the fetus\u2019s head. The device emits a sound for several seconds in an attempt to initiate a startle reflex and associated fetal acceleration, as is the case with other fetal assessment techniques such as fetoscopy (Polzin 1988; Smith 1986). The resulting acceleration of the fetus\u2019s heart rate is expected to be indicative of the fetus\u2019s well-being.<\/p>\n

The vibrations produced by the acoustic stimulation are emitted at low frequency and are considered safe for the baby. However, it is possible that the sound could induce a \u2018false negative\u2019 response and lead to unwarranted interventions. In order to avoid this, studies examining the use of this test should attempt to minimize the number of false positives. For example, studies that observed false negative results may have used stimuli with different intensity of sound or different models of artificial larynx.<\/p>\n

In addition to measuring a baby\u2019s heart rate, other tests are used to check for a healthy pregnancy. These tests include the fetal non-stress test (NST) and ultrasound. The NST is an important part of assessing the fetus\u2019 wellbeing but it can be difficult to interpret and can often be misleading. The baby\u2019s movements can also affect the outcome of these tests. It is therefore useful to add extra tests that will reliably indicate whether a baby is unwell.<\/p>\n

Vibratory and sound stimulation of the fetus has been suggested as one such test, but there is no evidence from randomised trials that this improves the ability of the NST or other tests to detect a sick baby. The PICO model is a helpful tool for formulating questions and searches for clinical studies or meta-analyses: Patient or population; Intervention; Comparison; Outcome.<\/p>\n

The fetal scalp blood sampling (FSCB) test is an invasive procedure that requires dilation of the cervix, rupture of the membranes and access to the fetus\u2019s presenting part. These limitations have been identified as potential reasons for inadequate fetal monitoring (East 2008). A noninvasive test that does not require the same preparation as the FSCB would be ideal.<\/p>\n

Results<\/h2>\n

Fetal vibroacoustic stimulation<\/a> has been found to improve the accuracy of antepartum cardiotocography by reducing the number of false negative responses (Serafini 1984; Trudinger 1980). This would be expected to reduce testing time and allow perinatal resources to be better utilised. However, the data on fetal distress and perinatal death were too few to draw any conclusions.<\/p>\n

There was a large variability between the trials in terms of study population, method of randomisation and outcome measure. One trial used sealed envelopes to randomly allocate women to a treatment group; the other trials did not mention any allocation concealment. There was also a wide variation in the intensity, frequency and duration of the acoustic stimuli.<\/p>\n

In one trial, the acoustic stimulus was emitted from an artificial larynx placed over the fetus\u2019 abdomen. It was activated by pressing a button and the resulting sound was transmitted to the mother\u2019s abdominal wall through the skin. The stimulation was then stopped for 3 seconds. The woman then rested for 10 minutes before another NST was performed. Computerised fetal heart rate (cCTG) data were recorded for the whole duration of the test, including the time interval after the acoustic stimulus was stopped. The data included FHR accelerations and decelerations, short-term variability (STV), long-term irregularity and approximate entropy (ApEn).<\/p>\n

The other trials used a vibrotactile stimulator that was placed over the woman\u2019s abdomen, with the fetus in semi-Fowler’s position. The stimulation was activated by a button and the resulting sound was passed to the fetus through the skin. The stimulus was then stopped for 3 seconds and the woman waited for a cCTG result. The acoustic stimulus was then repeated for 2 seconds and if the result was not reactive, another 10-minute interval was given before another NST was performed.<\/p>\n

The results of these studies varied considerably, with two of the trials reporting no measurable difference in the results between the groups. The results of the remaining studies showed that acoustic stimulation improved the reliability of the cCTG in low-risk pregnancies, but was not effective in high-risk pregnancies.<\/p>\n

Conclusions<\/h2>\n

Fetal acoustic stimulation may make tests on unborn babies’ well-being more effective. Studies [1-4] have shown that fetal sleeping periods can lead to falsely nonreactive tests, increasing the risk of unnecessary obstetric intervention. Attempts to arouse the fetus while it is sleeping or in a rest-activity cycle include a change in maternal position, physical activity, glucose ingestion, sound stimulation, light stimulation, and manual fetal manipulation. Of these, the only stimuli that consistently evoke responses in normal fetuses are acoustic and vibrotactile ones. The latter involves stimulating the uterus with a hand-held electronic device which transmits brief acoustic stimuli through the mother’s abdominal wall to the fetus.<\/p>\n

In the case of fetal acoustic stimulation, it is thought that the stimuli induce a neural response in the fetus. The response is mediated through the autonomic nervous system, which regulates cardiovascular and hormonal functions. The effect of acoustic stimulation on the autonomic nervous system is measurable by computer analysis of fetal heart rate (FHR) tracings. The analysis compares FHR tracings before and after acoustic stimulation.<\/p>\n

This research indicates that the acoustic stimulus is associated with a significant increase in FM, accelerations, and short-term variability of FHR. It also increases the ACC and HVE of the FHR and decreases the DEC and STV. In addition, the acoustic stimulation results in a significantly increased fetoplacental movement.<\/p>\n

Other trials assessing the effectiveness of fetal vibroacoustic stimulation<\/a> as an adjunct to tests of fetal wellbeing have not been conducted to randomised design. Nevertheless, the findings of these studies indicate that fetal vibroacoustic<\/a> stimuli can increase the responsiveness of tests of fetal well-being, particularly the nonstress cardiotocograph test, and may therefore reduce the time required to achieve a reassuring biophysical profile or CTG.<\/p>\n

There is a need to study the effects of this technique on important outcomes such as maternal satisfaction, stress reaction, and perinatal outcome. Moreover, there is a need to assess the cost and safety of this procedure.<\/p>\n